This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the data on Novartis' Pluvicto as a treatment for mCRPC presented at ESMO 2023.
Ticker(s): NVSWho's the expert?
Institution: Tampa Oncology and Proton
- Radiation Oncologist at Tampa Oncology and Proton
- Manages between 5-10 patients with metastatic or castrate-resistant prostate cancer on a monthly basis
- Familiar with and reviewed the phase 3 data for the Pluvicto trial
Interview GoalTo discuss the current standard of care and the potential of Pluvicto (Lutetium 177Lu vipivotide tetraxetan) as a treatment for metastatic castration resistant prostate cancer (mCRPC) including the phase III study results of Pluvicto (Lutetium 177Lu vipivotide tetraxetan) in patients with mCRPC presented at ESMO 2023.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
